CDK4/6抑制剂abemaciclib专利技术分析

Analysis on Patent Technology of CDK4/6 Inhibitor Abemaciclib

细胞周期蛋白依赖性激酶(CDK)4/6是近年来抗肿瘤药物研发的热点。Abemaciclib是继palbociclib、ribociclib后FDA批准的第三款CDK4/6抑制剂,已于2020年12月在我国批准上市。本文对abemaciclib相关专利申请状况和专利技术发展脉络进行分析,以期为我国相关医药企业的药物研发和专利布局提供参考。

Cyclin-dependent kinase(CDK) 4/6 is a important target in the research and development of anti-tumor drugs in recent years. Abemaciclib is the third CDK4/6 inhibitor approved by FDA after palbociclib and ribociclib. It was approved by SFDA in December 2020. This article analyzes the status of abemaciclib related patent applications and the development context of patent technology, in order to provide references on the drug R&D and patent portfolio for related domestic pharmaceutical companies.